NeurAxis (NRXS) Expected to Announce Quarterly Earnings on Tuesday

NeurAxis (NASDAQ:NRXS) is projected to issue its results before the market opens on Tuesday, August 11th. Analysts expect NeurAxis to announce earnings of ($0.32) per share and revenue of $2.00 million for the quarter.

NeurAxis Stock Performance

NRXS opened at $7.09 on Monday. NeurAxis has a 1-year low of $2.20 and a 1-year high of $9.33. The firm has a 50-day moving average price of $6.92 and a two-hundred day moving average price of $6.64. The stock has a market capitalization of $88.46 million, a PE ratio of -3.85 and a beta of 1.49.

Institutional Investors Weigh In On NeurAxis

Institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp bought a new position in NeurAxis in the fourth quarter valued at about $139,000. Rosalind Advisors Inc. bought a new stake in NeurAxis during the 4th quarter worth about $1,299,000. Geode Capital Management LLC raised its holdings in NeurAxis by 48.8% during the 4th quarter. Geode Capital Management LLC now owns 75,653 shares of the company’s stock worth $343,000 after purchasing an additional 24,817 shares during the last quarter. Citadel Advisors LLC lifted its position in NeurAxis by 39.6% during the 3rd quarter. Citadel Advisors LLC now owns 35,627 shares of the company’s stock valued at $110,000 after purchasing an additional 10,103 shares during the period. Finally, Manatuck Hill Partners LLC bought a new position in shares of NeurAxis in the 2nd quarter valued at about $122,000. Institutional investors own 11.77% of the company’s stock.

About NeurAxis

NeurAxis (NASDAQ: NRXS) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic candidates for diseases of the central nervous system. The company leverages a proprietary approach to deliver small molecules and biologics across the blood–brain barrier, aiming to address conditions ranging from acute neural injury to chronic neurodegenerative disorders.

NeurAxis advances its pipeline through a combination of in-house research, external collaborations with academic medical centers and contract research organizations, and strategic licensing agreements.